Search results (1331)
« Back to PublicationsGuideline for the investigation and management of eosinophilia
Butt NM. et al, (2017), British Journal of Haematology, 176, 553 - 572
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
Middleton MR. et al, (2017), British Journal of Cancer
Patient and Physician Preferences for Treating Adjuvant Melanoma: A Discrete Choice Experiment
Beusterien K. et al, (2017), Journal of Cancer Therapy, 8, 37-50
FIRST-IN-CLASS, ORAL MUTANT IDH2 INHIBITOR REVERSES DIFFERENTIATION BLOCK IN ACUTE MYELOID LEUKAEMIA TO PRODUCE CLINICALLY MEANINGFUL RESPONSES
Vyas P., (2017), EXPERIMENTAL HEMATOLOGY, 53, S38 - S38
Protein interactions involving LARP1 in chemotherapy resistant ovarian cancer cells
Stavraka C. et al, (2017), CANCER RESEARCH, 77
Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients.
Ait-Tahar K. et al, (2017), Adv Hematol, 2017
Toward a Biology-Driven Treatment Strategy for Peripheral T-cell Lymphoma.
Hildyard C. et al, (2017), Clin Med Insights Blood Disord, 10
Toward a biology-driven treatment strategy for peripheral T-cell lymphoma
Hildyard CAT. et al, (2017), Clinical Medicine Insights: Blood Disorders, 10
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma
Goding C. et al, (2016), Genes and Development
Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
Timmerman JM. et al, (2016), BLOOD, 128
First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies
Postel-Vinay S. et al, (2016), EUROPEAN JOURNAL OF CANCER, 69, S7 - S8
Initial seeding of the embryonic thymus by immune-restricted lympho-myeloid progenitors.
Luis TC. et al, (2016), Nat Immunol, 17, 1424 - 1435
Preliminary biomarker and pharmacokinetic analysis from the completed dose escalation part of the first-in-human Phase I study evaluating MP0250, a multi-DARPin (R) blocking HGF and VEGF-A, in patients with advanced solid tumors
Dawson K. et al, (2016), EUROPEAN JOURNAL OF CANCER, 69, S133 - S133